Reports Q3 revenue $3.6M, consensus $3.6M. Cash, cash equivalents, restricted cash, and marketable securities as of September 30 were approximately $1.1B compared to $925.1M at December 31, 2018. The increase was primarily due to proceeds from Sage's follow-on public offering completed in February 2019. "Sage's approach to drug discovery and development has led to the significant progress we have made during the third quarter," said Jeff Jonas, M.D., chief executive officer of Sage Therapeutics. "We are pleased with the execution by our teams at Sage. Our Depression Franchise continues to advance, our SAGE-217 studies are progressing well, and the launch of ZULRESSO in postpartum depression is yet another step towards upending conventional wisdom about treating psychiatric disorders. On top of this, our early stage pipeline continues to expand. We are looking forward to the upcoming data readout for SAGE-217, and we are excited by the possibilities in front of us."